Avatrombopag 对比安慰剂治疗胃肠道肿瘤持续性化疗所致血小板减少症:II 期 ACT-GI 试验
这项多中心随机双盲安慰剂对照 II 期试验在胃肠道肿瘤持续性化疗所致血小板减少症(CIT)患者中比较 avatrombopag 与安慰剂。因预设疗效停止标准达标,试验提前终止;P<.001)。
要点
- Avatrombopag 可有效纠正持续性 CIT 并预防复发,主要终点达标率 70% 对 17%。
- Avatrombopag 组不良事件 78%、严重不良事件 17%,安慰剂组分别为 46% 和 0%。
- 无严重不良事件与试验药物相关,无治疗相关不良事件导致死亡或停药。
核心结论
- 在胃肠道肿瘤持续性 CIT 患者中,avatrombopag 可有效管理该并发症,结果令人期待。
研究设计与样本
- 多中心、随机、双盲、研究者发起的美国 II 期试验,按 1:1 分配 avatrombopag 或安慰剂。
- 入组胃肠道肿瘤持续性 CIT 患者:尽管有足够时间从上一周期恢复,化疗周期第 1 天血小板仍≤85×10^9/L。
- 主要终点为成功纠正 CIT 并预防复发:血小板恢复至≥100×10^9/L、无化疗剂量调整/延迟、研究周期结束时无 CIT 复发(血小板≥100×10^9/L)。
- 因达到预设疗效停止标准,数据与安全监察委员会在计划中期分析时提前关闭入组。
主要发现
- 研究周期治疗结束时中位(IQR)血小板计数:avatrombopag 组 157(136–202)×10^9/L,安慰剂组 72(68–134)×10^9/L。
- 不良事件发生率 avatrombopag 组 78%、安慰剂组 46%;严重不良事件发生率分别为 17% 和 0%。
- 无严重不良事件与试验药物相关;无治疗相关不良事件导致死亡或停用试验药物。
临床怎么用
- 对于胃肠道肿瘤持续性 CIT 且血小板≤85×10^9/L 的患者,avatrombopag 可考虑用于纠正血小板并保障按时足量化疗。
局限性
- 试验因疗效提前终止,样本量小(avatrombopag 组 23 例、安慰剂组 24 例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chemotherapy-induced thrombocytopenia (CIT) is a challenging and common complication of cytotoxic chemotherapy in patients with GI cancers. There is no widely available approved treatment. Avatrombopag is a potent, second-generation oral thrombopoietin receptor agonist promising for CIT management. METHODS: We conducted a multicenter, randomized, double-blind, investigator-initiated US trial of avatrombopag or placebo (1:1) in GI cancer patients with persistent CIT (platelets ≤85 × 109/L on day 1 of a chemotherapy cycle despite adequate time to recover from the prior cycle). The primary end point was successful correction of CIT and prevention of recurrence (defined as recovery of platelets to ≥100 × 109/L, no chemotherapy dose modification/delay, and prevention of CIT recurrence [platelets ≥100 × 109/L] at end of the on-study cycle). RESULTS: The trial was closed to enrollment by the data and safety monitoring board at the planned interim analysis after meeting prespecified stopping criteria for efficacy. Sixteen of 23 patients (70% [95% CI, 47 to 87]) receiving avatrombopag achieved the primary end point versus 4/24 patients (17% [95% CI, 5 to 37]) receiving placebo (Z = 3.67, P < .001). The median (IQR) platelet count at the end of the on-cycle treatment period was 157 (136-202) × 109/L with avatrombopag versus 72 (68-134) × 109/L with placebo. Adverse events (AEs) and serious AEs occurred in 78% and 17% of patients receiving avatrombopag and 46% and 0% of patients receiving placebo, respectively. No serious AEs were study drug-related. There were no treatment-related AEs leading to death or discontinuation of study drug. CONCLUSION: In this randomized, placebo-controlled trial, avatrombopag was efficacious in the management of persistent CIT in patients with GI cancers. These findings are promising for a common, challenging oncologic complication that prevents delivery of full-dose, on-time, cancer-directed therapy.
引用
- Al-Samkari H, Shatzel JJ, Panch SR, et al. Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial. J Clin Oncol. 2026. PMID: 42441933. doi:10.1200/JCO-26-00568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。